TODAY'S MARKET INTELLIGENCE
Hengrui Medicine Subsidiary Receives Clinical Trial Approval for SHR-7012 Injection
English summary
Hengrui Medicine's subsidiary has received clinical trial approval for SHR-7012 injection, allowing the drug to enter clinical stage and enriching the company's R&D pipeline.
The English text is machine translated and may require verification against the Chinese version.
Browse today's intelligence